Nektar Therapeutics Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Nektar Therapeutics (NKTR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-05.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-03-05
- Nektar Therapeutics right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- Nektar Therapeutics right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- Nektar Therapeutics right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-06-30 was $0.00.
- Nektar Therapeutics right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00.
- Nektar Therapeutics right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Nektar Therapeutics right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $1.06M, a 50.45% decline from fiscal 2020.
- Nektar Therapeutics right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $2.13M, a 96.30% decline from fiscal 2019.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-05 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $0.00 10-K · filed 2024-03-05 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $0.00 10-Q · filed 2022-11-04 | $0.00 derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $0.00 10-Q · filed 2022-08-05 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $0.00 derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $0.00 derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $1.06M 10-K · filed 2024-03-05 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $1.06M 10-Q · filed 2022-11-04 | $1.06M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $1.06M 10-Q · filed 2022-08-05 | $1.06M derived: sum of 3 quarters · filed 2023-02-28 | $1.06M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $1.06M 10-Q · filed 2022-05-06 | $1.06M derived: sum of 2 quarters · filed 2023-02-28 | $1.06M derived: sum of 3 quarters · filed 2023-02-28 | $1.06M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $2.13M 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $2.13M 10-Q · filed 2021-11-05 | $3.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $2.13M 10-Q · filed 2021-08-06 | $3.80M derived: sum of 3 quarters · filed 2022-03-01 | $58.53M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $2.13M 10-Q · filed 2021-05-07 | $3.80M derived: sum of 2 quarters · filed 2022-03-01 | $58.53M derived: sum of 3 quarters · filed 2022-03-01 | $58.53M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $56.40M derived: sum of 2 quarters · filed 2022-03-01 | $56.40M derived: sum of 3 quarters · filed 2022-03-01 | $57.69M 10-K · filed 2022-03-01 |
| 2019-09-30 | $54.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $54.74M derived: sum of 2 quarters · filed 2020-11-06 | $56.02M 10-Q · filed 2020-11-06 | $56.02M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $1.29M 10-Q · filed 2020-08-07 | $1.29M derived: sum of 3 quarters · filed 2021-02-26 | |
| 2019-03-31 | $1.29M 10-Q · filed 2020-05-08 | $1.29M derived: sum of 2 quarters · filed 2021-02-26 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $0.00 10-K · filed 2021-02-26 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |